Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.

MEGA-9 [85261-19-4]

Imprimer

Référence NB-64-10640-100mg

Conditionnement : 100mg

Contactez votre distributeur local :

Téléphone : +1 850 650 7790

Demander plus d'informations

Contactez votre distributeur local :

Téléphone : +1 850 650 7790

Remove All

MEGA-9

(Synonyms: Nonanoyl-N-Methylglucamide) Copy Product Info

Synonyms: Nonanoyl-N-Methylglucamide

Catalog No. T20992 Copy Product Info

Purity: 99.9%

MEGA-9 (Nonanoyl-N-Methylglucamide) solubilizes membrane protein and can be used as a nonionic detergent.

Cas No. 85261-19-4

For research use only—not for human use. No sales to individuals. Use as intended only.

Select Batch

Purity:99.9%

Appearance:Solid

Color:White

Product Introduction

MEGA-9 AI Summary

MEGA-9 exhibits significant antiviral activity against various strains of HIV1, notably inhibiting HIV1 NL4.3 in human MT4 cells with an IC50 of 0.0023 μg/mL and an EC90 of 44.0 ng/mL. It also demonstrates activity against HIV1 3B in human HOS cells (IC50 of 10.0 nM) and other HIV1 strains with EC50 values ranging from 15.0 nM to greater than 200.0 nM. Additionally, it targets the CXCR4 receptor with an IC50 of 13.0 nM, showing low binding affinity for other chemokine receptors. Pharmacokinetically, the compound displays good oral bioavailability in dogs (80.0%), high permeability (86.0 nm/s at pH 7.4), and a moderate stability in human liver microsomes (67.0% at 0.5 μM). Moreover, MEGA-9 interacts with cytochrome P450 enzymes, inhibiting CYP2C19 (20% inhibition), CYP2D6 (IC50 of 1600-1640.0 nM), and CYP3A4 (35% inhibition). It has a high intrinsic clearance rate in rat liver microsomes and is rapidly metabolized and eliminated from the system. In addition to its antiviral properties, MEGA-9 also shows inhibitory effects on human HDAC6 enzyme activity and possesses moderate affinity for the CXCR4 receptor (Ki of 23.0 nM). However, its activity against SARS-CoV-2 and other viral infections appears limited, with low inhibition percentages observed against SARS-CoV-2 induced cytotoxicity. The compound exhibits systemic pharmacokinetic parameters such as changes in Cmax, AUC, and clearance rates when combined with ritonavir, suggesting potential drug-drug interactions. Oral bioavailability in mice is low (2.4%-2.54%), with a maximum plasma concentration of 117.32 nM at an oral dose of 30 mg/kg. These diverse bioactivities and pharmacokinetic properties highlight MEGA-9 as a compound of interest for further drug development and antiviral research..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	MEGA-9 (Nonanoyl-N-Methylglucamide) solubilizes membrane protein and can be used as a nonionic detergent.
Synonyms	Nonanoyl-N-Methylglucamide

Chemical Properties

Molecular Weight	335.44
Formula	C₁₆H₃₃NO₆
Cas No.	85261-19-4
Smiles	CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Relative Density.	1.172 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 3.36 mg/mL (10.02 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.9812 mL	14.9058 mL	29.8116 mL	149.0580 mL
5 mM	0.5962 mL	2.9812 mL	5.9623 mL	29.8116 mL
10 mM	0.2981 mL	1.4906 mL	2.9812 mL	14.9058 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

Keywords

SerineProteaseSerine ProteaseMEGA-9MEGA9MEGA 9Elastase

Related Tags: MEGA-9 chemical structure | MEGA-9 formula | MEGA-9 molecular weight